| scholarly article | Q13442814 |
| P50 | author | Andrea V Margulis | Q41066288 |
| Kristin Palmsten | Q87904754 | ||
| P2093 | author name string | Sonia Hernández-Díaz | |
| Soko Setoguchi | |||
| Amanda R Patrick | |||
| P2860 | cites work | Why Most Discovered True Associations Are Inflated | Q24273233 |
| Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data | Q30664587 | ||
| Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data | Q31052150 | ||
| Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients | Q31974256 | ||
| Associations of depression and depressive symptoms with preeclampsia: results from a Peruvian case-control study | Q33300600 | ||
| On the validity of area-based income measures to proxy household income | Q33327578 | ||
| Prescription medication borrowing and sharing among women of reproductive age. | Q33367364 | ||
| Persistence and compliance to antidepressant treatment in patients with depression: a chart review | Q33468671 | ||
| Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data | Q33521786 | ||
| Cigarette smoking during pregnancy and risk of preeclampsia: a systematic review. | Q33751894 | ||
| Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies | Q33930498 | ||
| SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants | Q33989845 | ||
| Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy | Q34182166 | ||
| Pathophysiology of preeclampsia and the role of serotonin | Q34194389 | ||
| Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies. | Q34295849 | ||
| Switching antidepressants for treatment-resistant major depression | Q34383659 | ||
| Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. | Q34564611 | ||
| Treatment non-adherence in affective disorders. | Q34592227 | ||
| Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review | Q34595672 | ||
| Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates | Q34597029 | ||
| Recent Insights into the pathogenesis of pre-eclampsia | Q34682287 | ||
| Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis | Q34935593 | ||
| Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters. | Q34989213 | ||
| Antidepressant discontinuation and risk of suicide attempt: a retrospective, nested case-control study | Q35003289 | ||
| The biology of preeclampsia | Q35037064 | ||
| Assessment and treatment of depression during pregnancy: an update | Q35561511 | ||
| Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study | Q35720653 | ||
| International Classification of Diseases-9th revision coding for preeclampsia: how accurate is it? | Q35851227 | ||
| Use of antidepressant medications during pregnancy: a multisite study | Q36955493 | ||
| Pharmacotherapy of mood disorders | Q37120683 | ||
| Recent developments in the design of anti-depressive therapies: targeting the serotonin transporter | Q37232938 | ||
| Selective serotonin reuptake inhibitor use and risk of gestational hypertension | Q37326892 | ||
| A prospective evaluation of the directionality of the depression-inflammation relationship | Q37359708 | ||
| Changes in the prevalence of pre-eclampsia in Akershus County and the rest of Norway during the past 35 years | Q39763200 | ||
| Non-adherence with psychotropic medications in the general population | Q39880242 | ||
| Assessing the Saskatchewan database for outcomes research studies of depression and its treatment | Q40752483 | ||
| Preeclampsia: an excessive maternal inflammatory response to pregnancy | Q40824430 | ||
| Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein | Q41595625 | ||
| Risks and benefits of selective serotonin reuptake inhibitors in the treatment of depression | Q41702163 | ||
| Effect of maternal fluoxetine administration on uterine blood flow, fetal blood gas status, and growth | Q43937285 | ||
| Noradrenaline-induced vasoconstriction in the uterine vascular bed of pregnant rats chronically treated with L-NAME: role of prostanoids. | Q44576737 | ||
| Preeclampsia risk in relation to maternal mood and anxiety disorders diagnosed before or during early pregnancy | Q46131446 | ||
| Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. | Q46906958 | ||
| Impact of preeclampsia and gestational hypertension on birth weight by gestational age. | Q47194029 | ||
| Depression and anxiety in early pregnancy and risk for preeclampsia. | Q51082104 | ||
| Sensitivity and specificity of computerized algorithms to classify gestational periods in the absence of information on date of conception. | Q51896801 | ||
| Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn. | Q51917251 | ||
| Duration of human singleton pregnancy. A population-based study. | Q55055472 | ||
| Switching Antidepressants After a First Selective Serotonin Reuptake Inhibitor in Major Depressive Disorder | Q56038601 | ||
| In vitro perfusion studies on human umbilical arteries. I. Vasoactive effects of serotonin, PGF2 alpha and PGE2 | Q68733177 | ||
| Effects of serotonin on vascular tone of isolated human placental chorionic veins | Q68774751 | ||
| Serotonin-induced vasoconstriction in human placental chorionic veins: interaction with prostaglandin F2 alpha | Q70600072 | ||
| Effect of hypertensive diseases in pregnancy on birthweight, gestational duration, and small-for-gestational-age births | Q71716223 | ||
| Preeclampsia and preterm birth subtypes in Nova Scotia, 1986 to 1992 | Q73593280 | ||
| Comparison of risk factors for preeclampsia and gestational hypertension in a population-based cohort study | Q74628793 | ||
| Increased fetal blood pressure response to maternal norepinephrine after pharmacological inhibition of norepinephrine uptake in pregnant sheep | Q80024759 | ||
| Increasing use of antidepressants in pregnancy | Q80426520 | ||
| Associations between immunologic, inflammatory, and oxidative stress markers with severity of depressive symptoms: an analysis of the 2005-2006 National Health and Nutrition Examination Survey | Q84775964 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pre-eclampsia | Q61335 |
| pregnant person | Q104720811 | ||
| P304 | page(s) | 988-997 | |
| P577 | publication date | 2012-03-22 | |
| P1433 | published in | American Journal of Epidemiology | Q4744243 |
| P1476 | title | Elevated risk of preeclampsia in pregnant women with depression: depression or antidepressants? | |
| P478 | volume | 175 |
| Q35195714 | Antenatal depressive symptoms and the risk of preeclampsia or operative deliveries: a meta-analysis |
| Q46220428 | Antidepressant medication use, depression, and the risk of preeclampsia |
| Q36793021 | Antidepressant use and gestational hypertension: does evidence support causality? |
| Q36793025 | Antidepressant use and gestational hypertension: does evidence support causality? Reply letter |
| Q34158083 | Antidepressant use and risk for preeclampsia |
| Q55379353 | Antidepressant use during pregnancy and the risk of developing gestational hypertension: a retrospective cohort study. |
| Q45996838 | Autoimmune conditions and comorbid depression in pregnancy: examining the risk of preterm birth and preeclampsia. |
| Q38334947 | Beginning and duration of pregnancy in automated health care databases: review of estimation methods and validation results |
| Q47562172 | Bias from restricting to live births when estimating effects of prescription drug use on pregnancy complications: A simulation. |
| Q48026593 | Bupropion sustained release for pregnant smokers: a randomized, placebo-controlled trial |
| Q28385738 | Constructing Causal Diagrams for Common Perinatal Outcomes: Benefits, Limitations and Motivating Examples with Maternal Antidepressant Use in Pregnancy |
| Q99348808 | Depressed mood and anxiety as risk factors for hypertensive disorders of pregnancy: a systematic review and meta-analysis |
| Q35917575 | Depression and anxiety in pregnancy and postpartum in women with mild and severe preeclampsia |
| Q38186686 | Depression and cardiovascular disease in women: is there a common immunological basis? A theoretical synthesis |
| Q59136492 | Drug Transport at the Brain and Endothelial Dysfunction in Preeclampsia: Implications and Perspectives |
| Q36068009 | Effects of Fluoxetine on Human Embryo Development |
| Q37325241 | Elevated risk of adverse obstetric outcomes in pregnant women with depression |
| Q30591555 | Gestational diabetes and hypertensive disorders of pregnancy among women veterans deployed in service of operations in Afghanistan and Iraq |
| Q34807301 | Harnessing the Medicaid Analytic eXtract (MAX) to Evaluate Medications in Pregnancy: Design Considerations |
| Q89347707 | Hypertensive Disorders of Pregnancy |
| Q92393610 | Inflammation, depression and cardiovascular disease in women: the role of the immune system across critical reproductive events |
| Q30966054 | Methodological considerations in assessing the effectiveness of antidepressant medication continuation during pregnancy using administrative data |
| Q55021720 | Paternal use of antidepressants and offspring outcomes in Sweden: nationwide prospective cohort study. |
| Q90618374 | Patterns of prenatal antidepressant exposure and risk of preeclampsia and postpartum haemorrhage |
| Q38174445 | Patterns of prescription of antidepressants and antipsychotics across and within pregnancies in a population-based UK cohort |
| Q27009185 | Perinatal depression--the fourth inflammatory morbidity of pregnancy?: Theory and literature review |
| Q58112980 | Preeclampsia by maternal reasons for immigration: a population-based study |
| Q35559923 | Preeclampsia, placental insufficiency, and autism spectrum disorder or developmental delay |
| Q37238197 | Premenstrual Syndrome and Subsequent Risk of Hypertension in a Prospective Study |
| Q39456421 | Risk of gestational hypertension and preeclampsia in women who discontinued or continued antidepressant medication use during pregnancy |
| Q47136710 | Risk of preeclampsia after gestational exposure to selective serotonin reuptake inhibitors and other antidepressants: A study from The Norwegian Mother and Child Cohort Study |
| Q38305749 | Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence |
| Q36176031 | The Pre-Eclampsia Ontology: A Disease Ontology Representing the Domain Knowledge Specific to Pre-Eclampsia |
| Q34936521 | The effects of antenatal depression and antidepressant treatment on placental gene expression |
| Q36860205 | The effects of maternal depression and maternal selective serotonin reuptake inhibitor exposure on offspring |
| Q38722632 | The risks associated with prenatal antidepressant exposure: time for a precision medicine approach |
| Q38375187 | The use of antidepressants in pregnancy: focus on maternal risks. |
| Q89216620 | Treatment of depression, anxiety, and trauma-related disorders during the perinatal period: A systematic review |
| Q34237681 | Treatment of nonpsychotic major depression during pregnancy: patient safety and challenges |
| Q64077840 | Use of antidepressants and anxiolytics in early pregnancy and the risk of preeclampsia and gestational hypertension: a prospective study |
Search more.